MicroRNAs are small non-coding RNAs that participate in a variety of biological processes, and dysregulation of miRNA is always associated with cancer development and progression. Aberrant expression of miR-148b has been found in some types of cancer, but its expression and potential biological role in pancreatic cancer are still largely unknown. In this study, our data showed that miR-148b was significantly downregulated in 48 pairs of human pancreatic cancer tissues and five cell lines. Further, the deregulated miR-148b was correlated with increased tumor size, late TNM stage, lymphatic invasion, distant metastasis and worse prognosis in pancreatic cancer. Functional studies indicated overexpression of miR-148b dramatically suppressed the growth of cancer cells, attributable to induction of apoptosis and cell cycle arrest at S phase. Meanwhile, miR-148b remarkably inhibited invasion and enhanced chemosensitivity of pancreatic cancer cells.
Introduction
MicroRNAs are a class of small non-coding RNAs, which contain of about 22 nucleotides.
MicroRNAs bind to partially complementary sequences in the 3'-untranslated region (UTR) of specific target mRNA, resulting in either mRNA degradation or translation inhibition (1) .
Growing evidence suggests that microRNAs play an important role in various biological processes, including cell proliferation, development and differentiation (2, 3) . Furthermore, increasing numbers of microRNAs have been observed in various types of cancer and may be involved in modulating cancer cell behaviors (4) (5) (6) (7) . These data emphasize the importance of microRNAs in cancer development and provide new insights into understanding the molecular mechanism of tumorigenesis.
Pancreatic cancer is one of the most common cancers worldwide and the fourth leading cause of cancer related deaths in the United States (8). The poor prognosis is due to its tendency for late presentation, early metastasis and poor response to chemotherapy (9). The development of pancreatic cancer is a multistep process with accumulation of genetic and epigenetic alterations (10, 11) . Microarray studies have identified a number of microRNAs that are up-or down-regulated in pancreatic cancer. Recently, miR-148b has been shown to be deregulated in some other types of cancers, such as overexpressed in ovarian cancer (12) and lung cancer (13) , while downregulated in pancreatic cancer (14, 15) , gastric cancer (16) and colorectal cancer (17) .
However, the exact role of miR-148b in carcinogenesis of pancreatic cancer has not been revealed yet.
Hence, the present study evaluated the miR-148b expression in human pancreatic cancer tissues and cell lines. Furthermore, the correlations between dysregulation of miR-148b and clinical pathological characteristics were analyzed. Also, the effects of miR-148b on proliferation, invasive ability and chemosensitivity of pancreatic cancer cells were identified.
Moreover, the microRNA software indicated that AMP-activated protein kinase Į1 (AMPKĮ1) might be the downstream target of miR-148b. AMPK is a highly conserved energy-sensing serine/threonine kinase, which can maintain energy stores and enhance oxidative metabolism ( . AMPK is a heterotrimeric complex consisting of a catalytic (Į) and two regulatory (ȕ and Ȗ) subunits. Two isoforms are known for catalytic subunit (Į1, Į2) and they are encoded by different genes (20) . Recently, some studies have demonstrated that AMPK plays critical regulatory roles in cancer cell growth and tumorigenesis of cancer cell (21) (22) (23) . For example, some research demonstrated that activation of AMPKĮ1 suppressed the growth of human colon cancer cell (24) , while some other research showed that AMPKĮ1 could increases chondrosarcoma cancer cell migration (25) , which indicated that AMPKĮ1 was controversial in different cancer cells.
Moreover, Kato K et al displayed that AMPKĮ1-RNAi could inhibit the growth of pancreatic cancer (26) . Therefore, we selected the AMPKĮ1 as the target for miR-148b to further explore the effects of miR-148b/AMPKĮ1 signal on pancreatic cancer.
Materials and methods

Patients and Tumor Tissues
Human pancreatic cancer tissues (PC) and corresponding adjacent normal pancreas tissues (NP) were acquired by surgical removal from 48 patients at Pancreatic Disease Institute, Union Hospital (Wuhan, China) between 2007 and 2009 (30 males and 18 females; median age, 56 years; age range, 31-77 years). None of the patients had received chemotherapy or radiotherapy before surgery excision. The original histopathological reports were obtained from each case and the diagnosis of pancreatic cancer was confirmed. Immediately after surgical removal, tissue samples were either snap-frozen in liquid nitrogen (for miR-148b and AMPKĮ1 extraction) or fixed in 10% buffered formalin solution and then embedded in paraffin (for histological analysis).
Informed consent was obtained from all patients before surgery and the study protocol was approved by the ethics committee of Huazhong University of Science and Technology.
Immunohistochemistry
AMPKĮ1 expression was determined by immunohistochemistry as our previously described (27) .
Sections of paraffin-embedded tissue were incubation with the primary antibody to AMPKĮ1 (dilution 1:100, Santa Cruz) and a rabbit antigoat horseradish peroxidase-labeled secondary 
RNA Isolation and Quantitative Real-time Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
Total RNA from tissue specimens and cell lines was prepared using Trizol reagent (Invitrogen).
To quantify mature miR-148b expression, total RNA was polyadenylated using poly-A polymerase based First-Strand Synthesis kit (TaKaRa Bio, Japan) according to the manufacturer's protocol. To quantify AMPKĮ1 expression, total RNA was converted to cDNA using M-MLV reverse transcriptase (Invitrogen). QRT-PCR was performed using the quantitative SYBR Green PCR kit (TaKaRa) after reverse transcription. The expression of miR-148b was normalized to that of U6 small nuclear RNA. One primer is microRNA specific and the other is a universal primer.
AMPKĮ1 expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
The relative amounts of miR-148b and AMPKĮ1 were measured with the 2 ǻǻCT method. All qRT-PCR reactions were performed in triplicate. The primers used in qRT-PCR are shown in Table S1 .
Cell Culture
The pancreatic cancer PANC-1, ASPC-1, BXPC-3, SW1990 and Miapaca-2 cell lines were obtained from American Type Culture Collection (ATCC, Manassas, USA); they were tested and authenticated for genotypes by DNA fingerprinting. These cell lines were passaged for less than 6 months after resuscitation, and no re-authorization was done. Cells were cultured in RPMI-1640 mediums supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin.
MicroRNA and RNA interference
MiR-148b mimics (miR-148b), miR-148b negative control (miR-NC), miR-148b inhibitor Table S2 , and sequences of LV-shAMPKĮ1 was consistent with the sequences of siAMPKĮ1-2 that was the most effective.
Colony formation assay
Twenty-four hours after transfection, 300 transfected cells were placed in a fresh 12-well plate and maintained in RPMI-1640 containing 10% FBS for 12 days. Colonies were fixed with methanol and stained with 0.1% crystal violet solution for 15 min and photographed. Colonies of more than 50 cells were counted (29) .
Cell viability assay
Cell survival was determined by MTT assays as previously described (30) . Cells were seeded in 96-well plates at densities of 5× 10 3 cells per well, treated with 50nM miR-148b and/or different concentrations of 5-Fluorouracil (5-FU) (Sigma-Aldrich), Gemcitabine (GEM) (Eli Lilly and Co., Suresnes Cedex, France) and Cisplatin (DDP) (Sigma-Aldrich) for 48h and then estimated by a colorimetric assay using MTT dye (5 mg/mL). The absorbance was determined in an ELISA plate reader using an activation wavelength of 570 nm. Cell viability values were determined by comparison with untreated control cells for three independent experiments, each of which used n = 6 replicate wells per assay condition.
Evaluation of cell apoptosis
To quantify cell apoptosis, Annexin V/PI staining was performed. Briefly, cells were collected, 
Cell cycle distribution analysis
Cells were harvested by trypsinization, washed with cold PBS, and fixed in 70% ethanol overnight at -20 . After fixation, cells were treated with DNA staining solution (3.4 mM Tris-Cl (pH 7.4), propodium iodide, 0.1% triton X-100 buffer and 100ȝg/ml RNase A). Cell cycle analysis was accomplished by FACS flow-cytometry.
Matrigel invasion assay
Cell invasion experiment was assessed using the Matrigel Invasion Chamber of pore size 8 mm 
Western blot analysis
Western blot was performed as described recently (31), with some modifications. Total cell lysates (40ȝg) were denatured and resolved on SDS-polyacrylamide gels, and transferred onto polyvinylidene difluoride membranes. After blocking in 5% skim milk, membranes were probed with primary antibodies followed by horseradish peroxidase-linked secondary antibodies. The membrane was visualized using ECL (Pierce) and exposed to a Kodak X-OMAT film 
Statistical analysis
All results are expressed as means ±standard deviation (SD). Comparisons between groups were performed with the unpaired t test. The relationships between miR-148b expression and clinic characteristics were analyzed by Ȥ 2 tests. Pancreatic cancer patient survival was analyzed by log-rank test. The relationship between miR-148b and AMPKĮ1 expression was explored by Spearman's correlation. Values were considered to be significantly different at P<0.05. All statistical analysis was performed using SPSS 13.0 software. Table 1) .
Results
MiR-148b is deregulated in pancreatic cancer and correlates with clinical characteristics
Downregulation of miR-148b correlates with worse prognosis of patients with pancreatic cancer
As shown in Fig. 1C , the survival analysis revealed that lower miR-148b expression levels significantly correlated with reduced survival (P<0.05). This result suggested that deregulation of miR-148b might promote the progress in pancreatic cancer.
MiR-148b inhibits cell proliferation in vitro
As shown in Fig. 2A (Fig. 2C and D) . (Fig. 3A) . Moreover, the results demonstrated that the S phase was significantly increased in both PANC-1 (24.02%±3.52% vs 44.10%±3.49%) and BXPC-3 cells (21.12%±3.00% vs 28.99%±2.32%) following transfection with miR-148b after 48 h (Fig. 3B) .
Moreover, we observed that the invasion ability of PANC-1 cells was significantly inhibited following transfection with miR-148b (miR-148b group, 63±8 cells / HP; miR-NC group, 117±10 cells / HP; HP means high power magnification field) (Fig. 3C) . The similar results were also observed in BXPC-3 cells.
MiR-148b enhances chemosensitivity of pancreatic cancer cells
After transfected with miR-148b mimics for 48h, the IC50 of PANC-1 cells was significantly Fig. S2A and B) . QRT-PCR results demonstrated that miR-148b expression levels were obviously increased in LV-miR-148 transfected tumors compared with control tumors (Supplemental Fig. S2C ).
AMPKĮ1 is a direct target of miR-148b
To demonstrate the direct interaction between miR-148b and AMPKĮ1, we cloned 3'UTR sequences that contain the predicted target site (wild type, WT) or mutated sequences (mutant type, MUT) of miR-148b into the pGL3 control vector, respectively (Fig. 4A) . The results showed that co-transfection of miR-148b mimics significantly decreased the firefly luciferase activity of the reporter with wild type 3'UTR but not that of the mutant reporter (Fig. 4B) (Fig. 4C) . Our results also showed that the expression levels of AMPKĮ1 were dramatically decreased in miR-148b-overexpressed tumors from mice, compared to control tumors (Supplemental Fig. S2D ).
AMPKĮ1 is overexpressed in human pancreatic cancer tissues and cells and inversely correlates with miR-148b levels
The results demonstrated that the AMPKĮ1 expression levels in pancreatic cancer tissues were significantly higher than in adjacent normal pancreatic tissues (Supplemental Fig. S3A ).
Simultaneously, the immunohistochemical analysis also showed that AMPKĮ1 was overexpressed and located primarily to cytoplasm in pancreatic cancer cells. In contrast, normal pancreatic tissue samples exhibited weak AMPKĮ1 immunoreactivity (Supplemental Fig. S3B ). Although AMPKĮ1 expression levels in pancreatic cancer tissues always exceeded those of matched normal pancreas, some patient-to-patient variability was also obviously. We also found that AMPKĮ1 was upregulated in miR-148b-downregulated pancreatic cancer lines (Supplemental Fig. S3C) . Further, as shown in supplemental Fig. S3D , a significant inverse correlation was observed between AMPKĮ1 and miR-148b expression in pancreatic cancer tissues (Spearman's correlation, r = -0.5998; P < 0.001) and adjacent noncancerous tissues (r = -0.5093; P < 0.001). This result further confirms that endogenous AMPKĮ1 was regulated by miR-148b.
Downregulation of AMPKĮ1 inhibits growth of pancreatic cancer cell in vitro and in vivo
Western blot results demonstrated that all of 3 siRNA targeting AMPKĮ1 were able to effectively knockdown the expression of AMPKĮ1 in PANC-1 and BXPC-3 cells. The MTT assays showed that the silencing of AMPKĮ1 significantly reduced growth of pancreatic cancer cells (Fig. 5A) .
The qRT-PCR and western blot results showed that LV-shAMPKĮ1 significantly silenced AMPKĮ1 expression and LV-AMPKĮ1 effectively rescued the above silencing of AMPKĮ1 in mRNA and protein levels ( 
Downregulation of AMPKĮ1 induced apoptosis, cell cycle arrest and inhibits invasion of pancreatic cancer cells
Compared to NC group, AMPKĮ1-RNAi increased the cell apoptosis (Supplemental Fig. S5A) and caused a significant S phase arresting of PANC-1 cells (Supplemental Fig. S5B ). We also observed that PANC-1 cells invasion ability was significantly inhibited following AMPKĮ1-RNAi (Supplemental Fig. S5C ). On the other hand, overexpression of AMPKĮ1 rescued miR-148b-induced apoptosis and cell cycle arrest and invasion inhibition of pancreatic cancer PANC-1 cells (Supplemental Fig. S6A, B Our clinical data showed that miR-148b deregulation was significantly associated with large tumor size, late TNM stage, lymphatic invasion and distant metastasis, which further indicated that deregulated miR-148b might facilitate the development of pancreatic cancer. Furthermore the survival analysis revealed that downregulation of miR-148b correlated with shorter survival time of pancreatic cancer patients. Hence, determination of miR-148b expression could be a novel biomarker to predict the prognosis of pancreatic cancer patients.
Furthermore, overexpression of miR-148b could significantly inhibit proliferation by inducing apoptosis and cell cycle arresting at S phase, whereas, deregulation of miR148b promoted cell growth. On the other hand, overexpression of miR-148b inhibited invasion of pancreatic cancer cells. This study first showed that miR-148b functioned as a tumor suppressor in pancreatic cancer cells. As we known, chemotherapy resistance is still a major challenge for the therapy of pancreatic cancer (36, 37). Therefore, the identification of biomarkers beneficial for chemoresistance and understanding the related mechanisms will display advisable strategies to overcome this problem. Interestingly, our study showed that miR-148b mimics transfection promoted the sensitivity of PANC-1 and BXPC-3 cells to 5-FU, GEM and DDP. Therefore, therapeutic approaches to introduce miR-148b into cancer cells might be potentially feasible not only in prohibiting the development of tumorigenesis but also in sensitizing cancer cells to chemotherapeutic drugs.
To explore the mechanisms underlying the inhibition of pancreatic cancer cell growth mediated by miR-148b, we next set out to identify the potential target genes of miR-148b. The bioinformatics analysis indicates that AMPKĮ1 may be the potential target for miR-148b. Moreover, AMPKĮ1 (38, 39) . Thus, we applied luciferase activity assay to identify the effect of miR-148b on AMPKĮ1 expression. The luciferase activity data showed that miR-148b was able to directly target the 3'UTR of AMPKĮ1. QRT-PCR and western blot results showed that the overexpression of miR-148b downregulated AMPKĮ1 expression in PANC-1 and BXPC-3 cells by both interfering and degrading mRNA. Therefore, the present results showed that AMPKĮ1 was upregulated in pancreatic cancer tissues and cell lines and inversely correlated with miR-148b expression. These data confirmed that miR-148b could downregulate the expression of AMPKĮ1, which also implied that AMPKĮ1 might be a promoter in pancreatic cancer.
There have accumulating evidences in recent years for an intrinsic link between cancer and metabolism. Highly anabolic malignant cells need to constantly increase protein translation and DNA synthesis to support their ongoing growth (40, 41) , ultimately resulting in changes of cellular energy levels-detected by AMPK (18, 42) , which suggests that AMPK is required for malignant progression. Previously, some research confirmed that activation of AMPKĮ1 inhibited the growth of human cancer cell by effecting mTOR signaling (24, 43) , which suggested that AMPKĮ1 might be an inhibitor for cancer. On the other hand, other research showed that AMPKĮ1 could increase cell migration through up-regulation of integrin (25, 44) levels in cancer cells, which also indicated that AMPKĮ1 might be a promoter in cancer. In the present study, we further reveal that knockdown of AMPKĮ1 with RNAi inhibited pancreatic cancer cell growth both in vitro and vivo, consistent with Kato K results in vivo (26) . These contradictory results suggest that the role of AMPKĮ1 is heterogeneous in different cancers.
Moreover, silencing of AMPKĮ1 caused apoptosis, cell cycle S-phase arrest, and inhibited invasion of pancreatic cancer cells, which was similar to the phenotypes induced by miR-148b overexpression. Furthermore, AMPKĮ1 overexpression could rescue the growth suppressive effect of miR-148b, and further rescue miR-148b-induced apoptosis and cell cycle arrest and invasion inhibition of pancreatic cancer. These findings strongly indicated that AMPKĮ1 might be a promoter in development of pancreatic cancer. In conclusion, our present study demonstrated that miR-148b was downregulated in pancreatic cancer tissues and cell lines. And the low expression pattern was observed to be significantly correlated with increased tumor size, late TNM stage, lymphatic invasion, distant metastasis and worse prognosis. We also found that miR-148b can inhibit cell proliferation, invasion and enhance chemosensitivity of pancreatic cancer by targeting AMPKĮ1. Our data implicated the potential application of miR-148b as a tumor suppressor in pancreatic cancer therapy and also as a tumor marker for predicting prognosis. 
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